Details
Category: Volume 08 Issue 07 July 2020
Hits: 1094

Title: Comparing efficacy of Topiramate and Valproate in migraine prophylaxis in rural Bengal -A Randomized Controlled Trial

Authors: Abhijit Das, Ratul Banerjee, Shankar Prasad Nandi, Ananya Mandal

 DOI: https://dx.doi.org/10.18535/jmscr/v8i7.57

Abstract

Migraine is second most common cause of headache which is responsible for reduction in the quality of life affects near about 15% of women and 6% of men over a period of 1 year.1 Affect boys and girls in similar fashion in prepubescent age group, but girls are affected more than boys after that with a rise of incident in fourth decade of life. Topiramate and sodium valproate are the two widely accepted and approved anti-epileptics used for treatment of migraine prevention. Head to head studies are few with these drugs and we have taken MIDAS Score with reduction of frequency and duration of migraine headache as primary and European quality of life index with EQ-VAS score for quality of life assessment, all these parameters are not founded in any study. A randomized control trial was done at Bankura Sammilani Medical College with population from rural Bengal, data was taken and detail and appropriate statistical analysis was done with appropriate software. Both the drugs were found very much effective for migraine prophyalxis and improving quality of life.

Keywords: Migraine, Valproate, Topiramate.

References

  1. Kasper DL, Fauci AS, Hauser SL, Longo DL, Jameson JL, Loscalzo J. Harrison’s Manual of Internal Medicine. 19. 1. New York: McGraw Hill Education; 2016.215.
  2. Lipton RB, Bigal ME, Diamond M, Freitag F, Reed ML, Stewart WF; AMPP Advisory Group. Migraine prevalence, disease burden, and the need for preventive therapy. Neurology. 2007;68(5):343-9.
  3. Rasmussen BK. Epidemiology of headache. Cephalalgia.1995;15(1):44-67.
  4. Osterhaus JT, Townsend RJ, Gandek B, Ware JE Jr. Measuring the functional status and well-being of patients with migraine headache. 1994 Jun; 34(6):337-43.
  5. Monzón MJ, Láinez MJ. Quality of life in migraine and chronic daily headache patients. 1998;18(9):638-43.
  6. D’Amico D, Usai S, Grazzi L, et al. The impact of primary headaches on patients’ lives: Italian experience with the MIDAS and the SF-36 questionnaires. Headache Care. 2004;1:123–8.
  7. Lucas C, Géraud G, Valade D, Chautard MH, Lantéri-Minet M. Recognition and therapeutic management of migraine in 2004, in France: results of FRAMIG 3, a French nationwide population-based survey. 2006; 46(5):715-25.
  8. Silberstein SD.P ractice parameter: evidence-based guidelines for migraine headache (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology. 2000; 55(6):754-62.
  9. Evers S, Afra J, Frese A, Goadsby PJ, Linde M, May A, Sándor PS.EFNS guideline on the drug treatment of migraine - report of an EFNS task force.Eur J Neurol. 2006;13(6):560-72.
  10. Brunton LL, Hilal-Dandan R, Knollmann BC. Goodman Gilman’s The Pharmacological Basis Of Therapeutics. 13.New York: McGraw Hill;2018.318-9.
  11. Brandes JL, Saper JR, Diamond M, et al. Topiramate for migraine prevention: a randomized controlled trial. JAMA. 2004;291(8):965–73 Diener HC, Tfelt-Hansen P, Dahlof C, et al. Topiramate in migraine prophylaxis – results from a placebo-controlled trial with propranolol as an active control. J Neurol. 2004;251(8):943–50.  
  12. Chronicle E, Mulleners W. Anticonvulsant drugs for migraine prophylaxis. Cochrane Database Syst Rev. 2004;(3):CD003226.
  13. Welch KM, D’Andrea G, Tepley N, Barkley G, Ramadan NM. The concept of migraine as a state of central neuronal hyper excitability. Neurol Clin. 1990;8(4):817–28.
  14. Shank RP, Gardocki JF, Streeter AJ, Maryanoff BE. An overview of the preclinical aspects of topiramate: pharmacology, pharmacokinetics, and mechanism of action. Epilepsia. 2000;41 (Suppl 1):S3–S9.
  15. Schurks M, Diener HC, Goadsby P. Update on the prophylaxis of migraine. Curr Treat Options Neurol. 2008;10 (1):20–9.
  16. Guo Y, Han X, Yu T, Yao G. Meta-analysis of efficacy of topiramate in migraine prophylaxis. Neural Regen Res. 2012; 7(23): 1806–11.
  17. Kinze S, Clauss M, Reuter U, Wolf T, Dreier JP, Einhäupl KM et al. Valproic acid is effective in migraine prophylaxis at low serum levels: a prospective open-label study. Headache. 2001;41(8):774-8.
  18. Bartolini M, Silvestrini M, Taffi R, Lanciotti C, Luconi R, Capecci M, Provinciali. L Efficacy of Topiramate and Valproate in Chronic Migraine. Clinical Neuropharmacology.2005; 28(6):277-9.
  19. Bavrasad R, Nejad S, Yarahmadi A, Sajedi S, Rahim F. Assessment of the Middle Dose of Topiramate in Comparison with Sodium Valproate for Migraine Prophylaxis: A Randomized-Double-Blind Study. International Journal of Pharmacology.2010; 6(5): 670-675.

Corresponding Author

Ratul Banerjee

MD (Pharmacology), MO SUPY, Salt Lake Subdivisional Hospital